Molecule intelOpportunity: ModerateEssential

Fluvoxamine

13 brands · 8 companies · product forms

ATC: N06AB08

Opportunity snapshot

Launch attractiveness
35
Market saturation
22
Price room
38
Regulatory risk
0
13
brands
8
companies
Rs 432.2
median price
12
price points
2.5x
price spread
100
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 15%

Price room

Across observed sources and strengths
CheapestRs 345.16
MedianRs 432.2
Most expensiveRs 864.5
Spread2.5×
Sources: DRAP-official, DVAGO, Servaid

max/min price ratio 2.50x across 12 trusted points (Rs 345.16-864.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 4 live products for Fluvoxamine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(38) + 20% low-competition(78) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

8 canonical companies and 13 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 2.50x across 12 trusted points (Rs 345.16-864.5). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.